Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

Baricitinib was effective and safe for severe hair loss treatment over 6 months.

People with Fibromyalgia Syndrome often have skin symptoms, which can worsen their quality of life and increase depression.

Baricitinib significantly regrows hair in severe alopecia areata patients.

The Breast Utility Instrument was developed to assess quality of life in breast cancer patients.

Tofacitinib helped most teenagers in the study regrow hair with mild side effects.

People with mycosis fungoides/Sézary syndrome have a much lower quality of life.

The CLASI is a reliable tool for measuring the severity of cutaneous lupus erythematosus.

Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.

The Polish Skindex-29 is a reliable and valid questionnaire for assessing the quality of life in Polish dermatology patients.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.

Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.

Ustekinumab significantly improved sexual function and quality of life for people with moderate to severe psoriasis.

Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.

Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.

Baricitinib is effective and safe for treating severe alopecia areata.

Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.

Adalimumab significantly improved symptoms and quality of life in two patients with Hidradenitis Suppurativa.

Measuring bald patch size can help grade hair loss severity, with photograph-based evaluation being more reliable.

Higher EULAR/ACR scores in SLE patients predict more organ damage.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Disease-specific tools better assess quality of life in alopecia areata patients.

Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.

Skin and mucous symptoms are key for diagnosing autoimmune connective tissue diseases.

A change in SALT scores of 42 or 43 indicates meaningful improvement in alopecia areata treatment.

The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

The SAALIQ is a reliable tool for measuring the impact of alopecia areata on Spanish-speaking patients' quality of life.

Psoriasis patients have more comorbidities, including autoimmune diseases and other health issues, than those without psoriasis.